Volume : 12, Issue : 06, June – 2025
Title:
FORMULATION AND DEVELOPMENT OF PIMECROLIMUS GEL FOR SYMPTOMATIC RELIEF OF ERUPTIVE XANTHOMAS
Authors :
Ayesha Fatima, Juveriya Rahman, Shagufta Tabassum, Balaji Reddy*
Abstract :
The present study focuses on the formulation and development of a topical gel containing Pimecrolimus, aimed at providing symptomatic relief from eruptive xanthoma, a lipid metabolism disorder characterized by sudden eruptions of yellow-red papules. Given Pimecrolimus immunomodulatory properties and effectiveness in managing inflammatory skin conditions, it was chosen as the active pharmaceutical ingredient for gel formulation. The formulation was developed using Carbopol 934 as the gelling agent, along with excipients like polyethylene glycol, ethanol, methylparaben, and triethanolamine. Four formulations (F1–F4) were prepared and evaluated for various physicochemical parameters, including pH, viscosity, spreadability, drug content, and in vitro drug release. Among all, formulation F3 demonstrated optimal characteristics, showing a drug content of 92.52%, viscosity of 32,000 cps, and spreadability of 25.6 g·cm/sec. In vitro drug release studies using Franz diffusion cells indicated a sustained release of 95.55% over 8 hours. The gel also remained physically and chemically stable over three months under different storage conditions, as per ICH guidelines. Overall, the developed Pimecrolimus gel exhibited favorable topical application properties, effective drug release, and stability, making it a promising candidate for further clinical evaluation in the treatment of eruptive xanthoma.
KEY WORDS: Pimecrolimus, Eruptive Xanthoma, Topical Gel, Calcineurin Inhibitor, Carbomer, Triethanolamine, Drug Release, Franz Diffusion Cell, Skin Disorders, Gel Formulation, Stability Studies, In-vitro Evaluation.
Cite This Article:
Please cite this article in press Balaji Reddy et al, Formulation And Development Of Pimecrolimus Gel For Symptomatic Relief Of Eruptive Xanthomas.., Indo Am. J. P. Sci, 2025; 12(07).
Number of Downloads : 10
References:
1. Jain NK. Controlled and Novel Drug Delivery. 1st ed. New Delhi: CBS Publisher and Distributors; 2001. p. 100-29.
2. Darwhekar G, Jain DK, Paditar VK. Formulation and evaluation of transdermal drug delivery system of clopidogrel bisulfate. Asian J Pharm Life Sci 2011;1:269-78.
3. Shingade GM, Aamer Q, Sabale PM, Grampurohit ND, Gadhave MV. Review on: Recent trend on transdermal drug delivery system. J Drug Deliv Ther 2012;2:66-75.
4. Frontiers in Pediatrics. Early application of Pimecrolimus 1% cream in infants with atopic dermatitis reduces allergen sensitization: An observational study. Front Pediatr. 2023;11:1102354.
5. Wahn U, Kapp A, Staab D, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus. Pediatrics. 2002;110(6):e72
6. Rajasekaran Aiyalu , Formulation and evaluation of topical herbal gel for the treatment of arthritis in animal model, Brazilian Journal of Pharmaceutical Sciences vol. 52, n. 3, jul./sep., 2016
7. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074–82.
8. U.S. Food and Drug Administration. Elidel (Pimecrolimus) cream 1% prescribing information. Available from: https://www.accessdata.fda.gov
9. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of pimecrolimus cream 1% in children with atopic dermatitis. J Am Acad Dermatol. 2005 Apr;52(4):581–9.
10. Wollenberg A, Oranje A, Deleuran M, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol. 2010;24(9):1176–93.
11. Meingassner JG, Schmook FP, Czarnetzki BM, et al. Pimecrolimus: an anti-inflammatory drug with a low potential for systemic immunosuppression. Skin Pharmacol Appl Skin Physiol. 2002;15(2):90–100.
12. Alagusundaram, M.; Jain, N.K.; Begum, M.Y.; Parameswari, S.A.; Nelson, V.K.; Bayan, M.F.; Chandrasekaran, B. Development and Characterization of Gel-Based Buccoadhesive Bilayer Formulation of Nifedipine. Gels 2023, 9, 688.
13. K.A. Sampatrao, Formulation development and evaluation of Silymarin gel, Research gate, October 2011
14. Dantas MG, Reis SA, Damasceno CM, Rolim LA, Rolim-Neto PJ, Carvalho FO, Quintans-Junior LJ, Almeida JR. Development and Evaluation of Stability of a Gel Formulation Containing the Monoterpene Borneol. ScientificWorldJournal. 2016;2016:7394685.
15. N Ranjith Kumar, Development of formulation and evaluation of topical micro emulsion gel loaded with terbinafine HCL micro emulsion, World Journal of Biology Pharmacy and Health Sciences, 2024, 19(02), 074–089.